After participating in this educational activity, the participant should be better able to: 1. Assess the likelihood of success of continuous renal replacement therapy in critically ill children after hematopoietic stem cell transplant. 2. Evaluate key metabolic and management factors that can heighten the practitioner's concern for increased risk of mortality in pediatric oncology patients status post hematopoietic stem cell transplant who are being treated with continuous renal replacement therapy. 3. Interpret contemporary serum biomarkers that can provide clinical insight into the inflammatory response in pediatric oncology patients status post-hematopoietic stem cell transplant who are being treated with continuous renal replacement therapy. Unless otherwise noted, the faculty's, staff's, and authors' spouse(s)/life partner(s) (if any) have nothing to disclose. The authors have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity. All faculty and staff in a position to control the content of this CME activity have disclosed that they have no financial relationship with, or financial interests in, any commercial companies pertaining to this educational activity. Visit the Pediatric Critical Care Medicine Web site (www.pccmjournal.org) for information on obtaining continuing medical education credit.
H ematopoietic stem cell transplantation (HSCT) is being utilized in the treatment of an ever-expanding list of malignant and nonmalignant disorders. Despite its potential for cure, HSCT may be associated with significant morbidity. Organ dysfunction is not uncommon and may result from a number of factors, including endothelial injury, infections, graft vs. host disease (GVHD), and medications.
Renal failure seems to be particularly common among this group of patients (1, 2) . Although multifactorial in etiology, the need for nephrotoxic medications, including chemotherapeutics, antibiotics, and immunosuppressants, contributes to renal dysfunction among this group. Furthermore, successful care of the HSCT patient frequently requires a high volume of intravenous fluid, including the need for blood products, which increase the risk of fluid overload. As a result of renal dysfunction and this need for highvolume intravenous intake, these patients may require renal replacement therapy (3) . Continuous renal replacement therapy (CRRT) seems to be the modality of choice in the intensive care unit (ICU) (4) . Furthermore, this therapy has been advocated to be of benefit in this patient population for reasons other than fluid elimination, including immunomodulation, most notably, among those with respiratory failure (5, 6) .
However, the utilization of this therapy is both invasive and resource intensive and, thus, ideally should be associated with a high likelihood for success. A recent report (7) demonstrated an encouraging pediatric ICU (PICU) survival rate of 45% for HSCT patients who required CRRT. In that study, 35% of those HSCT patients treated with CRRT, who required mechanical ventilation, survived through PICU discharge. Other pediatric studies (8 -11) have reported survival rates ranging from 19% to 45% in HSCT patients, who develop acute renal failure. However, none of these studies assessed long-term outcomes in this high-risk population. A better understanding of the impact that this therapy has on both short and long-term outcomes among these children and the factors that influence these outcomes is essential to the optimal implementation of this therapy. Consequently, the purpose of this study was to assess short-and long-term survival in pediatric allogeneic HSCT patients treated with CRRT and to identify clinical factors associated with survival. CRRT is an important modality for use in critically ill children with renal dysfunction and/or renal fluid overload. However, its use in the complex setting of pediatric oncology patients with interventions such as HSCT and critical illness with various components of multiple organ dysfunction is controversial. This report by Rajasekaran et al begins to provide some insight into this challenging question. After completing this CME activity, physicians should be better able to assess the likelihood of success of CRRT in critically ill children after HSCT, evaluate key metabolic and management factors that may lead to an increased risk of mortality in pediatric oncology patients treated with CRRT, and interpret contemporary serum biomarkers that can provide clinical insight into the inflammatory response in this patient population.
MATERIALS AND METHODS
We performed a retrospective analysis of all courses of CRRT in the ICU of a tertiary care pediatric oncology center from January 2003 through December 2007. Study patients were identified by screening the databases of the ICU and of the HSCT service. Only those patients who had undergone allogeneic HSCT before CRRT were included in this analysis. During that time period, the only modality of CRRT offered at our institution was citratebased continuous veno-venous hemodialysis. The study was approved by the Institutional Review Board and the need for informed consent was waived.
Medical records were reviewed, and abstracted data included demographics, diagnoses, survival, clinical and laboratory data pertaining to markers of inflammation as well as pulmonary, renal, cardiac, and hepatic function. Medical diagnoses included the underlying condition for which the transplant was performed as well as the acute diagnoses that mandated intensive care admission. These acute diagnoses were categorized into pulmonary, cardiovascular/sepsis, neurologic deterioration, or renal failure based on the primary reason for PICU admission. Other basic demographic data abstracted included the age, weight, and gender of the patient, the Pediatric Risk of Mortality (PRISM) III score both at the time of admission to the PICU and at CRRT initiation, the number of days post transplant at the time of CRRT initiation, and whether the HSCT was the first or second transplant. Although PRISM scores were developed to be used with data from the day of PICU admission, other CRRT studies have utilized PRISM scores determined from data derived on the day of CRRT initiation (7, 12) ; thus, we included these scores in our analysis.
The causes of death for the cohort were extracted from the HSCT database, and whenever available, the cause of death was determined from an autopsy.
In addition to demographics, data pertaining to the level of inflammation, the degree of pulmonary support and function, the extent of hemodynamic support in the form of vasoactive infusions, the amount of fluid overload and renal function, as well as the status of the liver were collected and/or calculated. Abstracted data pertaining to the level of inflammation included the diagnosis of acute or chronic GVHD, as well as the absolute neutrophil counts (ANC) and C-reactive protein (CRP) levels assessed at the start of CRRT, after 48 hrs of CRRT, and at the end of CRRT. For patients who died, end values were the last levels determined before death. (In all cases, these end values were assessed within 48 hrs of death; in no case was the end CRP value the same as prior values.) Pulmonary data included the level of respiratory support, oxygen saturation, and blood gas values at the start of CRRT and after 48 hrs of CRRT. The level of support was categorized as invasive mechanical ventilation, noninvasive ventilation including continuous positive airway pressure and high flow, humidified nasal cannula oxygen, or simply supplemental facial or nasal cannula oxygen. The PaO 2 /FIO 2 (P/F) ratio was calculated for the above delineated two time points. To determine the nature of lung injury, chest radiographic findings were abstracted and categorized as focal, diffuse, or clear, and subsequently, as unilateral or bilateral. The initial P/F ratio was determined based on the arterial blood gas measurement assessed most closely to the start of CRRT. Patients were categorized by P/F ratio for analysis into those satisfying acute respiratory distress syndrome criterion (P/F ratio of Ͻ200), those satisfying acute lung injury criterion (P/F ratio of Ͻ300), or those satisfying neither (13) . The degree of hemodynamic support was determined by the number of vasoactive infusions utilized both before CRRT and within 24 hrs of CRRT initiation. Renal data determined and assessed included blood urea nitrogen (BUN) and creatinine levels, as well as an estimated glomerular filtration rate and the percent volume overload at the start of CRRT. The glomerular filtration rate was calculated, using the Schwartz equation (14) . Percent fluid overload was calculated based on the formula described by Goldstein: [(Fluid In-Fluid Out (L))/ (admission weight(kg)) ϫ 100]. It was calculated for both 48 hrs and 7 days before CRRT (12) . For analysis, percent fluid overload was assessed as both a continuous variable and as a categorical variable. As a categorical variable, percent fluid overload was dichotomized as Ն20% fluid overloaded, and subsequently, as Ն10%. Total bilirubin, alanine transferase, and aspartate transferase levels were utilized to assess hepatic function. BUN, creatinine, and bilirubin levels were assessed at a time point 4 wks before CRRT, at the start of CRRT, at 48 hrs of CRRT, and at the end of CRRT.
CRRT variables were also determined, including the length of the course in days and the amount of fluid removed daily. Patients were considered to have one course of CRRT, if it was discontinued, but resumed, before patient discharge from the PICU. CRRT is offered in our institution exclusively using the flow-controlled blood roller pump (Braun Diapact) machine. A standard protocol is initiated to maintain a postfilter ionized calcium of 0.25-0.35 mmol/L and a prefilter ionized calcium of 1.1-1.3 mmol/L by adjusting the infusion rates of citrate dextrose formula and calcium chloride (postfilter). Normocarb HF dialysate flow rates were calculated, using the formula 2000 mL/hr ϫ body surface area/1.73 m 2 ϭ mL/hr. Blood flow rates ranged from 2-4 mL/kg/min. Polyacrylonitrile filters were used until 2006, with polysulfone filters being used afterward. CRRT was initiated at the discretion of the PICU attending without predetermined initiation criteria. CRRT fluid removal rates were determined by the PICU physician, depending on the clinical status, fluid status, and hemodynamic stability of the patient.
For statistical analysis, categorical variables were summarized, using frequencies and percentages, and continuous variables were summarized, using means and standard errors of the mean. ANC was assessed as both a categorical and continuous variable, with neutropenia being defined as a cell count of Ͻ500 cells/L. The use of hemodynamic support was assessed as a binary variable comparing those patients who required vasoactive infusion(s) with those who did not. Cox proportional hazards regressions models were used to examine the relationship between demographic or clinical variables and length of survival. Hazard ratios (HRs) and 95% confidence intervals (CIs) were determined. Due to the small sample size, only bivariate analyses were considered. Although multivariable models were not constructed, correlations were examined between variables expected to be related. All analyses were conducted, using SAS Version 9.1 (SAS Institute Inc., Cary, NC). The significance level was set at .05.
RESULTS
Thirty-three courses of CRRT among 29 patients were identified. In 11 (33%) of the 33 courses, the patient was successfully discharged from the PICU; however, only one patient survived for Ͼ6 mos after PICU discharge. The median length of survival post CRRT initiation was 31 days (range, 2-405 days) (Fig. 1) . Of the 11 patients who survived their PICU admission, seven remained dependent on intermittent hemodialysis until their death, three recovered adequate renal function, and one opted for hospice/palliative care secondary to tumor relapse. All three patients who recovered renal function required a subsequent admission to the PICU during which they died. Two of these three required an additional course of CRRT during that admission.
Demographic Variables
Demographic characteristics of study patients are presented in Table 1 . Leukemia/lymphoma was the most common underlying condition for which the transplant was performed (n ϭ 18), followed by solid tumors (n ϭ 5), histiocytosis (n ϭ 3), and one each of myelodysplastic syndrome, aplastic anemia, and osteopetrosis. Respiratory failure was the pri- GFR, estimated glomerular filtration rate calculated using the Schwartz equation (13); HSCT, hematopoietic stem cell transplantation; CRRT, continuous renal replacement therapy; PRISM, Pediatric Risk of Mortality Score; PF, PaO 2 /FIO 2 ; ANC, absolute neutrophil count; BUN, blood urea nitrogen.
To convert torr to kPa, 1 torr ϭ .133 kPa.
mary reason for intensive care admission among the study population (n ϭ 25), followed by cardiovascular collapse/sepsis (n ϭ 6), neurologic deterioration (n ϭ 1), and renal failure (n ϭ 1). Seventeen (59%) of the 29 patients were males. Among demographic variables assessed, only weight was associated with length of survival such that for every kilogram increase in weight, there was a slight but significant decrease in the risk of death post CRRT ( Table 2 ). The median length of time from transplant to CRRT was 135 days (range, 7-1125).
The median PRISM III score on ICU admission was 14 (mean, 14.6 Ϯ 0 .6). The median PRISM III score at CRRT initiation was 17 (mean,16.3 Ϯ 0.8). Neither of these scores was significantly associated with length of survival.
Pulmonary Variables
During the 33 courses of CRRT, the majority of patients (n ϭ 27) were intubated and mechanically ventilated. In the remaining six courses, four patients received high flow, humidified oxygen (Vapotherm), one received nasal cannula oxygen, and one remained on room air alone. Of the 31 courses with a PF ratio determined at baseline, 17 satisfied acute respiratory distress syndrome criteria, and eight satisfied acute lung injury criteria; however, neither of these diagnoses was associated with an increased risk of death when compared with those who did not meet either criteria. No respiratory variable at the time of CRRT initiation was associated with survival, including the PF ratio, the level of support, or any blood gas index ( Table 1 ). The PF ratio at 48 hrs, however, was significantly associated with survival such that the higher the PF ratio, the greater the likelihood of survival (Tables 2 and 3 ). The median PF ratio at 48 hrs of CRRT was 222.2 (mean, 
Hemodynamic Variables
Vasoactive infusions were required in 19 courses of CRRT before initiation of this therapy. Within 24 hrs of starting CRRT, vasoactive infusions were required in an additional six courses (total of 25 of the 33 [lsqnb]76%] courses). Two or more vasoactive infusions were required in five (15%) courses before CRRT initiation and in 11 (33%) courses within 24 hrs after CRRT initiation. The number of vasoactive infusions at either time point was not statistically associated with length of survival.
Inflammatory Variables
Neither the ANC nor the CRP at the initiation of CRRT was associated with survival (Table 1) . However, both of these values determined at the end of CRRT were associated with survival (Tables 2 and 3 ). The median CRP at the end of CRRT was 4.4 mg/dL (mean, 8.4 Ϯ 2.0 mg/dL), whereas the median ANC was 3383 cells/L (mean, 3894.8 Ϯ 762.8 cells/L). The risk of death was increased by 6% for every 1-point increase in the final CRP level (HR, 1.057; 95% CI, 1.023, 1.092). Patients with neutropenia at the end of CRRT had more than a three-fold risk of death as compared with those without neutropenia (HR, 3.382; 95% CI, 1.310, 8.731). The ANC as a continuous variable was also associated with survival such that the higher the count, the less likely the risk of death (HR, 0.296; 95% CI, 0.105, 0.837). There seemed to be no association between CRP and neutrophil counts. Fifteen patients had documented acute or chronic GVHD. However, neither of these diagnoses was associated with an increased risk of death (HR, 1.571; 95% CI, 0.808, 3.056).
Renal/Continuous Veno-Venous Hemodialysis Variables
There were several renal variables associated with survival, including the BUN both at the initiation of CRRT and at 48 hrs into CRRT (Tables 2 and 3 ). Interestingly, including BUN values from both time points in a Cox proportional hazards model negated their effect, suggesting that the two values were closely related. Also, BUN values 4 wks before CRRT were associated with survival, although the results did not reach statistical significance (HR, 0.983; 95% CI, 0.965, 1.002). Serum creatinine was not statistically associated with survival. In addition, neither a fluid balance exceeding 10% body weight nor the estimated glomerular filtration rate at the start of CRRT were associated with survival. There were only two patients with a fluid balance exceeding 20%. Additionally, the numerical value of fluid overload as a continuous variable, at either 48 hrs or 7 days before CRRT, was not statistically associated with survival.
Hepatic Variables
Other than serum bilirubin, no marker of hepatic function was associated with survival. An increase in the bilirubin, both at the start of CRRT and 4 wks before CRRT, was associated with an increased risk of death (Tables 2 and 3 ). There was no association detected between bilirubin levels and CRP values.
Cause of Death
The primary cause of death of all study patients is listed in Table 3 . Forty-five percent (13 of 29) of all patients died of an infection-related complication. In contrast, only 10% (3 of 29) of patients had a death related to recurrence or progression of malignant disease. One patient was included in both categories, as his death was associated with both progression of his disease and invasive aspergillosis.
DISCUSSION
Our data represent a retrospective study of 29 patients who underwent 33 courses of CRRT analyzed with length of survival as the primary outcome in order to extract epidemiologic and clinical data associated with survival. The median duration of survival post CRRT initiation was 31 days with only one patient surviving Ͼ6 mos. This limited post CRRT survival complicates outcome analysis and may render PICU discharge alone an unsatisfactory end point. However, the widespread use of CRRT in pediatric critical care and the challenges of supporting HSCT patients with multiorgan failure mandate that investigators evaluate more rigorously the factors associated with outcome. In this single-center, retrospective study, higher serum bilirubin and BUN levels at the initiation of CRRT were associated with an increased risk of death. During CRRT, higher BUN and lower PF ratios after 48 hrs of therapy were associated with an increased risk of death. Finally, higher CRP and lower ANC values at the end of CRRT were also associated with increased risk of death.
The 33% PICU survival rate in this study is slightly lower than previously recorded. In the CRRT registry, 45% of HSCT patients survived to PICU discharge, including 35% of those who required mechanical ventilation. Although it is difficult to compare studies, one explanation for the lower survival rate in this current report is that the population potentially represented a higher-risk HSCT patient. Both PRISM scores and vasoactive infusion use seem higher in this report as compared with those in the registry paper, suggesting a higher acuity of illness. However, PRISM III scores were utilized in this report in contrast to PRISM II scores in the registry paper. The current report is the first to assess survival in these patients beyond PICU discharge. Therefore, given the potential that our population represented a higherrisk patient population, the long-term survival rate must be confirmed in additional multicentered studies.
The association between BUN levels and survival in this patient population is supported by the available literature. Bacigalupo and colleagues (15) previously demonstrated that elevated serum BUN levels at a number of time points are associated with increased mortality in HSCT patients. In addition, predictive scores of transplant-related mortality have been developed, which incorporate serum BUN, and not creatinine into the determination of the score (16) . It has been postulated that BUN levels reflect overall transplant-related illness, such as early GVHD as compared with serum creatinine values that primarily reflect only renal disease (15, 16) .
Larger body weights were found to offer a slight survival advantage in this study; however, positive fluid balance before CRRT was not associated with increased risk of death. This suggests that this finding is more associated with lean body mass rather than transient fluid weight gain. Prior research (6, 9, 17) has suggested a definite benefit to maintaining fluid homeostasis in critically ill children. Goldstein et al (12) initially reported that the percent of fluid overload at the initiation of CRRT was significantly lower in survivors than in nonsurvivors even after controlling for severity of illness with PRISM scores. DiCarlo et al (5) subsequently suggested that early hemofiltration may improve survival from acute respiratory distress syndrome after bone marrow transplantation. However, in both the CRRT registry analysis of pediatric HSCT patients and in the current report, a lower percentage of fluid overload at the initiation of CRRT was not associated with survival (7). It is possible that the initial reports resulted in the earlier implementation of CRRT among HSCT patients, tighter control of fluid balance before CRRT, and/or earlier transfers to the PICU, potentially preventing the major pathophysiological changes associated with the higher percentage of fluid overload. These earlier studies may well have modified practice patterns at our institution and, thus, likely influenced the results of this report. For example, there were no patients in this study who were 20% fluid overloaded for the 48 hrs before CRRT, and only two who were that fluid overloaded for the combined 7 days before CRRT. The median percent fluid overload was only 5.5% and 7.7%, respectively, for the 48 hrs and 7-day time periods before CRRT.
The finding of an association between elevated bilirubin levels and mortality in this study is not surprising. HSCT patients are prone to a variety of hepatic diseases, including veno-occlusive disease, GVHD, and hemochromatosis (18) . Wojnar et al (19) demonstrated increased serum bilirubin levels to be predictive of nonrelapse-related death in this patient population at day ϩ 100 post transplant. In addition, among HSCT patients requiring mechanical ventilation, elevated bilirubin levels have been associated with mortality (20) . Mechanical ventilation, in and of itself, has been found to be an independent risk factor for mortality in pediatric HSCT patients (21, 22) . A majority (81%) of our patients were mechanically ventilated before their CRRT course. Similarly, in the pediatric CRRT registry study, 72% of patients required ventilatory support (7) . In that study, PICU nonsurvivors required higher mean airway pressures at the end of their course when compared with the survivors. Although mean airway pressures were not assessed in the current study, lower PF ratios at 48 hrs of ventilation were associated with increased risk of dying. These findings suggest that the degree of lung injury may also influence the likelihood of survival.
In addition, lower CRP levels at the end of CRRT were associated with improved survival. CRP is emerging as a useful predictor of outcomes in a variety of patient populations (23) (24) (25) (26) . It is a pentameric, acute-phase reactant protein that is produced by hepatocytes, and it is uniquely sensitive to interleukin-6 (27) . Interleukin-6 plays a major role in the pathophysiology of transplant-related illness (28, 29) . CRP levels of Ͼ10 mg/dL have been found to correlate positively with the likelihood of multiple organ failure in pediatric HSCT patients (30) . The O-PRISM score which was specifically developed as a prognostic score for PICU survival among pediatric HSCT patients includes CRP as one of only three variables added to the traditional PRISM score (31) . In a subsequent paper from the group that developed the O-PRISM score, CRP levels that remained elevated after leukocyte engraftment (day ϩ 28 and beyond) correlated with poor prognosis, whereas temporarily high CRP levels during marrow aplasia did not significantly affect outcome (32) . Similarly, in our cohort, higher CRP at CRRT end was associated with an increased risk of death. In contrast, CRP levels obtained at the initiation of CRRT were not associated with an alteration in mortality risk. DiCarlo et al (5) suggested that lung injury after HSCT entails an inflammatory process that escalates insidiously and is difficult to terminate because of a dysregulated immune system. They suggested that continuous veno-venous hemofiltration may remove a sufficient amount of the inflammatory load to attenuate this process, thereby preventing the progression to multiple organ failure and death. The lower CRP at CRRT end may suggest a possible anti-inflammatory role for CRRT. However, many of these patients received other therapies that may have attenuated inflammation, including steroids and/or antimicrobials during their course of CRRT. Thus, caution must be exerted in attributing the changes in CRP levels to CRRT. However, these findings merit further study, given the contention that immune dysregulation and ensuing cytokine release may contribute more to transplantrelated mortality than the primary pathology (33) .
The reported causes of death in the current report would seem to support the contention that immune dysregulation and inflammatory disease contribute more to transplant-related mortality than the primary disease. Although causes of death were varied, 45% (13 of 29) of patients died from an infection-related process, whereas only 10% (3 of 29) died secondary to progression or recurrence of malignant disease. The number of patients dying from infection-related causes seems to mirror the percentage of PICU admissions for HSCT patients, who are related to infection which ranges from 36% to 42% in reported series (21, 34, 35) . In these reports, only a very small minority of patients received renal replacement therapy. The high percentage of patients who died from infectious processes in this study is of note because CRRT has the potential to diminish the ability of an immuncompromised patient to combat infections. CRRT has been reported to attenuate the immune response. For example, although there were intra-and interindividual variations of the immunologic parameters studied, Toft et al (36) demonstrated both proand anti-inflammatory cytokines in the ultrafiltrate of 15 critically ill patients with acute renal failure undergoing CRRT. Furthermore, CRRT has been found to have the potential to directly alter basic immune reactions, such as phagocytosis (37) . In a recent randomized clinical trial, early application of CRRT was deleterious in patients with sepsis and septic shock (38) . Given the inherent dysregulation of the immune system of the pediatric HSCT patient, further study regarding the impact of CRRT on immune function in this patient population is needed.
CONCLUSIONS
This report is limited by the fact that it is a retrospective, single-center study with a small sample size. The results of this study should be considered, at most, hypothesis generating. However, the study does seem to be among the first to report survival duration beyond PICU discharge in pediatric HSCT patients who have undergone CRRT. Given the resource-intensive and invasive nature of this therapy, further analysis of relatively long-term outcomes seems warranted. Such analysis is complicated by the many factors that influence survival among this patient population, including factors independent of the natural course of the disease, such as decisions to limit support. There is a need to better understand the impact of proinflammatory pathways on the HSCT patient, and the mechanisms by which therapies, such as CRRT, can be used to attenuate this inflammation. Such an improved understanding may ultimately result in better outcomes for these children. To that end, there is currently in process a prospective, multicentered study of this therapy among pediatric HSCT patients with acute lung injury. Despite its limitations, our current report suggests variables that may be associated with survival among this patient population. These findings are important in that they may generate hypotheses for further study. Furthermore, they may allow for more insightful discussions between healthcare providers and patients and families regarding implementation of this invasive and resource-intensive therapy. This work by Rajasekaran et al reveals that CRRT can be applied in critically ill pediatric oncology patients with HSCT; however, short and long-term outcomes indicate that there is much work to be done to define and implement the optimal utilization of this therapy in these extremely high-risk critically ill children. Clinical data that are available at the bedside appear to be able to help guide the physician in decisions to implement this new therapy and new biomarker data related to inflammation may be useful in the future. After completing this CME activity, physicians should be better able to assess the likelihood of success of CRRT in critically ill children after HSCT, evaluate key metabolic and management factors that may lead to an increased risk of mortality in pediatric oncology patients treated with CRRT, and interpret contemporary serum biomarkers that can provide clinical insight into the inflammatory response in this patient population.
